Technologies to Defeat Improvised Explosive Devices (IED’s)
Award amount
$940,875Program and phase
SBIR · Phase IIAward year
2006Award details
- Awarding agency
- Department of Defense
- Branch
- Navy
- Recipient company
- NANOTHERAPEUTICS, INC.
- Proposal award date
- 2005-11-14
- Contract end date
- 2006-11-14
- UEI
- GC2RFAZK8G64
- Solicitation number
- 2004.2
- Topic code
- N04-901
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine
- GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine
- Development of A Synthetic Typhoid Fever Vaccine as A Substitution of Vi Vaccine
- ORAL BUPRENORPHINE NANOPARTICLE FORMULATION
- ORAL BUPRENORPHINE NANOPARTICLE FORMULATION
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Technologies to Defeat Improvised Explosive Devices (IED’s)
- Roadside Explosive Device X-Ray Detecting System
- Field Collection and Analysis of Forensics and Biometric Evidence Associated with IEDs
- Selective Coatings For Microcantilever Explosive Detector (1000-828)
- Technologies to Defeat Improvised Explosive Devices (IED’s)
Research funding history
14 SBIR/STTR records share this UEI (2000–2013). Reported award amounts total $7,175,575. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense, National Aeronautics and Space Administration
Contractor profile
RESILIENCE GOVERNMENT SERVICES, INC.
Historical federal award activity, when published, is on that contractor profile. Matched by UEI only.
Agency intelligence
NAICS intelligence
This classification comes from the contractor profile, not from the SBIR award record.